Page 819 - Read Online

Alqahtani et al. Hepatoma Res 2020;6:70 I http://dx.doi.org/10.20517/2394-5079.2020.65 Page 13 of 15

carcinomas: a multicenter phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM). Ann Oncol 2006;17:vii73-7.
29. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
N Engl J Med 2010;362:1273-81.
30. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, et al. Gemcitabine alone or in combination with cisplatin in patients with
biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010;103:469-74.
31. Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two
randomised trials. Ann Oncol 2014;25:391-8.
32. Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin
for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 2019;30:1950-8.
33. André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, et al. Gemcitabine combined with oxaliplatin (GEMOX) in
advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-43.
34. Kim ST, Kang JH, Lee J, Lee HW, Oh SY, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for
advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 2019;30:788-95.
35. Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or
metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:1707-12.
36. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of
advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol 2019;5:824-30.
37. Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, et al. 615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS)
versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 2018;29.
38. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with
5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994;51:396-400.
39. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract
adenocarcinomas. Am J Clin Oncol 2000;23:425-8.
40. Chen JS, Jan YY, Lin YC, Wang HM, Chang WC, et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with
biliary tract carcinomas. Anticancer Drugs 1998;9:393-7.
41. Petekkaya I, Gezgen G, Roach EC, Solak M, Gullu I. Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine. J
buon 2012;17:796.
42. Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, et al. Second-line chemotherapy in biliary tract cancer: Outcome
and prognostic factors. Liver Int 2019;39:914-23.
43. Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, et al. Multivariate prognostic factors analysis for second-line chemotherapy in
advanced biliary tract cancer. Br J Cancer 2014;110:2165-9.
44. Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, et al. Second-line chemotherapy for advanced biliary tract cancer after failure
of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer
2015;121:3290-7.
45. Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, et al. Prediction of survival with second-line therapy in biliary tract
cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer 2019;111:94-106.
46. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann
Oncol 2014;25:2328-38.
47. Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active
symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced /
metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol 2019;37:4003.
48. Zheng Y, Tu X, Zhao P, Jiang W, Liu L, et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy
in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer 2018;119:291-5.
49. Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract
cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer 2017;116:561-7.
50. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015;47:1003-10.
51. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev
Clin Oncol 2018;15:95-111.
52. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic
implications. PLoS One 2014;9:e115383.
53. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by
next-generation sequencing. Oncologist 2014;19:235-42.
54. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, et al. Identification of targetable FGFR gene fusions in diverse cancers.
Cancer Discov 2013;3:636-47.
55. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, et al. Pemigatinib for previously treated, locally advanced or metastatic
cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84.
56. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced
cholangiocarcinoma. J Clin Oncol 2018;36:276-82.
57. Goyal L, Meric-Bernstein F, Hollebecque A, Valle J, Morizane C, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of
futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin